<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03356366</url>
  </required_header>
  <id_info>
    <org_study_id>2016-52</org_study_id>
    <secondary_id>2017-A00136-47</secondary_id>
    <nct_id>NCT03356366</nct_id>
  </id_info>
  <brief_title>MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis</brief_title>
  <acronym>SEP-MRI</acronym>
  <official_title>Magnetic Resonance Imaging Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is the first non-traumatic cause of disability in young people,&#xD;
      responsible for physical but also cognitive deficits. MS is an inflammatory demyelinating and&#xD;
      degenerative disease of the central nervous system. Recently, MRI technics have demonstrated&#xD;
      their sensibility to the different processes involved in MS. Particularly, MRI has evidenced&#xD;
      that the pathological process of MS is not restricted to the macroscopic lesions of the white&#xD;
      matter but also involves the normal appearing white and grey matter. In the normal appearing&#xD;
      brain tissue, demyelination, neuronal suffering and neuronal loss have been evidenced.&#xD;
      Moreover, MRI has demonstrated the existence of brain functional reorganization processes&#xD;
      that may limit the clinical expression of pathological injuries. Despite these important&#xD;
      findings, the pathological underpinnings of irreversible disability are largely unknown. The&#xD;
      present project aims to depict the main determinants of physical but also cognitive&#xD;
      disability in patients with MS. To do this, a longitudinal study including 70 patients with&#xD;
      MS using different MRI markers known to be sensitive to the different pathological aspects of&#xD;
      MS will be performed. The relationships between these markers and the progression of&#xD;
      disability will be assessed. Identification of the main pathological underpinnings of&#xD;
      irreversible disability of MS will provide the most relevant therapeutic targets.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the Expanded Disability Status Scale (EDSS) value (score from 0 to 20) constituing the actual international reference scale to measure the level of disability caused by parkinson disease</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Principal study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients pathological process will be assessed using MRI 3T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ancillary study 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients pathological process will be assessed using MRI 1,5T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ancillary study 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients pathological process will be assessed using MRI 7T</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI 3T</intervention_name>
    <description>Magnetic Resonance Imaging 3 Tesla</description>
    <arm_group_label>Principal study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI 1,5T</intervention_name>
    <description>Magnetic Resonance Imaging 1,5 Tesla</description>
    <arm_group_label>Ancillary study 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI 7T</intervention_name>
    <description>Magnetic Resonance Imaging 7 Tesla</description>
    <arm_group_label>Ancillary study 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient,&#xD;
&#xD;
          -  Patient affiliated to a health insurance plan&#xD;
&#xD;
          -  Patient having signed free and informed consent after receiving detailed,&#xD;
             understandable and honest information,&#xD;
&#xD;
          -  Patient with multiple sclerosis according to the criteria of Polman 2010&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with the usual contraindications to MRI (pace-maker, agitation, metal&#xD;
             splinters, claustrophobia etc.)&#xD;
&#xD;
          -  Patients at risk of non-compliance on examination: impaired understanding, confusion,&#xD;
             involuntary movements, poor tolerance of prolonged supine&#xD;
&#xD;
          -  Patients with known allergy to gadolinium&#xD;
&#xD;
          -  Patients with renal insufficiency&#xD;
&#xD;
          -  Patients unable to give their consent: disorders of the comprehension, disturbances of&#xD;
             vigilance, confusion ...&#xD;
&#xD;
          -  Pregnant and breastfeeding woman&#xD;
&#xD;
          -  Patients with a history of neurological or psychiatric pathology&#xD;
&#xD;
          -  Patients under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertrand AUDOIN, MD-PhD</last_name>
    <email>bertrand.audoin@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Camille DELANNOY</last_name>
    <email>camille.delannoy@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AUDOIN Bertrand</last_name>
      <email>bertrand.audoin@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

